The increase in the lean mass and fat mass in the compound‐1‐treated group could be caused to enhance insulin action in tissues by reduction of hyperglycemia and hyperinsulinemia toxicity by SSTR5 inhibition. The gene discussed is INS; the disease is Hyperinsulinemia.